Redirection of CD4+ and CD8+ T lymphocytes via a novel antibody-based modular targeting system triggers efficient killing of PSCA+ prostate tumor cells

Prostate

Volumn 74, Issue 13, 2014, Pages 1347-1358

  Arndt, Claudia ^a   Feldmann, Anja ^a,b   Töpfer, Katrin ^c   Koristka, Stefanie ^a   Cartellieri, Marc ^a,b   Temme, Achim ^c   Ehninger, Armin ^a,c   Ehninger, Gerhard ^c   Bachmann, Michael ^a,b  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^b INSTITUTE OF ION BEAM PHYSICS AND MATERIALS RESEARCH   (Germany)

^c UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

Author keywords

immunotherapy; PSCA; recombinant antibody; T cell redirection

Indexed keywords

IMMUNOTHERAPY; PSCA; RECOMBINANT ANTIBODY; T CELL REDIRECTION;

ANIMALS; ANTIGENS, NEOPLASM; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; GPI-LINKED PROTEINS; HUMANS; IMMUNOTHERAPY; MALE; MICE; NEOPLASM PROTEINS; PROSTATE; PROSTATIC NEOPLASMS;

EID: 84905915818     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.22851     Document Type: Article

References (42)

1. Drake CG,. Prostate cancer as a model for tumour immunotherapy. Nat Rev Immunol 2010; 10 (8): 580-593.
2. American Cancer Society. Cancer facts & figures 2013 [Internet]. Atlanta: American Cancer Society 2013 [cited 2013 Dec 1]. Available from: http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/ document/acspc-036845.pdf.
3. Walsh PC, DeWeese TL, Eisenberger MA,. Clinical practice. Localized prostate cancer. N Engl J Med 2007; 357 (26): 2696-2705.
4. Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC,. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999; 281 (17): 1591-1597.
5. Cheever MA, Higano CS,. PROVENGE (Sipuleucel-T) in prostate cancer: The first FDA-Approved therapeutic cancer vaccine. Clin Cancer Res 2011; 17 (11): 3520-3526.
6. Müller D, Kontermann RE,. Bispecific antibodies for cancer immunotherapy: Current perspectives. BioDrugs 2010; 24 (2): 89-98.
7. Stamova S, Koristka S, Keil J, Arndt C, Feldmann A, Michalk I, Bartsch H, Bippes CC, Schmitz M, Cartellieri M, Bachmann M,. Cancer immunotherapy by retargeting of immune effector cells via recombinant bispecific antibody constructs. Antibodies 2012; 1 (2): 172-198.
8. Byrne H, Conroy PJ, Whisstock JC, O'Kennedy RJ,. A tale of two specificities: Bispecific antibodies for therapeutic and diagnostic applications. Trends Biotechnol 2013; 31 (11): 621-632.
9. Wolf E, Hofmeister R, Kufer P, Schlereth B, Baeuerle PA,. BiTEs: Bispecific antibody constructs with unique anti-tumor activity. Drug Discov Today 2005; 10 (18): 1237-1244.
10. Hoffmann P, Hofmeister R, Brischwein K, Brandl C, Crommer S, Bargou R, Itin C, Prang N, Baeuerle PA,. Serial killing of tumor cells by cytotoxic T cells redirected with a CD19-/CD3-bispecific single-chain antibody construct. Int J Cancer 2005; 115 (1): 98-104.
11. Offner S, Hofmeister R, Romaniuk A, Kufer P, Baeuerle PA,. Induction of regular cytolytic T cell synapses by bispecific single-chain antibody constructs on MHC class I-negative tumor cells. Mol Immunol 2006; 43 (6): 763-771.
12. Baeuerle PA, Reinhardt C,. Bispecific T-cell engaging antibodies for cancer therapy. Cancer Res 2006; 69 (12): 4941-4944.
13. Stamova S, Feldmann A, Cartellieri M, Arndt C, Koristka S, Apel F, Wehner R, Schmitz M, Bornhäuser M, von Bonin M, Ehninger G, Bartsch H, Bachmann M,. Generation of single-chain bispecific green fluorescent protein fusion antibodies for imaging of antibody-induced T cell synapses. Anal Biochem 2012; 423 (2): 261-268.
14. Nagorsen D, Kufer P, Baeuerle PA, Bargou R,. Blinatumomab: A historical perspective. Pharmacol Ther 2012; 136 (3): 334-342.
15. Feldmann A, Stamova S, Bippes CC, Bartsch H, Wehner R, Schmitz M, Temme A, Cartellieri M, Bachmann M,. Retargeting of T cells to prostate stem cell antigen expressing tumor cells: Comparison of different antibody formats. Prostate 2011; 71 (9): 998-1011.
16. + T cells. J Immunol 2012; 189 (6): 3249-3259.
17. Arndt C, Feldmann A, von Bonin M, Cartellieri M, Ewen EM, Koristka S, Michalk I, Stamova S, Berndt N, Gocht A, Bornhäuser M, Ehninger G, Schmitz M, Bachmann M,. Costimulation improves the killing capability of T cells redirected to tumor cells expressing low levels of CD33: Description of a novel modular targeting system. Leukemia 2014; 28 (1): 59-69.
18. Arndt C, Feldmann A, Koristka S, Michalk I, Cartellieri M, Stamova S, von Bonin M, Bornhäuser M, Ehninger G, Bachmann M,. Redirection of immune effector cells by bispecific antibody systems for the treatment of acute myeloid leukemia [abstract]. Blood 2011; 118: 663-664.
19. Cartellieri M, Arndt C, Feldmann A, von Bonin M, Ewen EM, Koristka S, Michalk I, Stamova S, Berndt N, Gocht A, Bornhäuser M, Ehninger G, Schmitz M, Bachmann M,. TCR/CD3 activation and co-stimulation combined in one T cell retargeting system improve anti-tumor immunity. OncoImmunology 2013; 2 (12): e26770.
20. Arndt C, Cartellieri M, Aliperta R, Koristka S, Michalk I, Bornhäuser M, Ehninger G, Bachmann M, Feldmann A,. Enhancing the efficacy and specificity of antibody-based T cell retargeting strategies against hematological malignancies. Blood 2013; 122: 930.
21. Cunha AC, Weigle B, Kiessling A, Bachmann M, Rieber EP,. Tissue-specificity of prostate specific antigens: Comparative analysis of transcript levels in prostate and non-prostatic tissues. Cancer Lett 2006; 236 (2): 229-238.
22. Raff AB, Gray A, Kast WM,. Prostate stem cell antigen: A prospective therapeutic and diagnostic target. Cancer Lett 2009; 277 (2): 126-132.
23. Elsamman E, Fukumori T, Kasai T, Nakatsuji H, Nishitani MA, Toida K, Ali N, Kanayama HO,. Prostate stem cell antigen predicts tumour recurrence in superficial transitional cell carcinoma of the urinary bladder. BJU Int 2006; 97 (6): 1202-1207.
24. Argani P, Rosty C, Reiter RE, Wilentz RE, Murugesan SR, Leach SD, Ryu B, Skinner HG, Goggins M, Jaffee EM, Yeo CJ, Cameron JL, Kern SE, Hruban RH,. Discovery of new markers of cancer through serial analysis of gene expression: Prostate stem cell antigen is overexpressed in pancreatic adenocarcinoma. Cancer Res 2001; 61 (11): 4320-4324.
25. Carmo-Fonseca M, Pfeifer K, Schröder HC, Vaz MF, Fonseca JE, Müller WE, Bachmann M,. Identification of La ribonucleoproteins as a component of interchromatin granules. Exp Cell Res 1989; 185 (1): 73-85.
26. Koristka S, Cartellieri M, Arndt C, Bippes CC, Feldmann A, Michalk I, Wiefel K, Stamova S, Schmitz M, Ehninger G, Bornhäuser M, Bachmann M,. Retargeting of regulatory T cells to surface-inducible autoantigen La/SS-B. J Autoimmun 2013; 42: 105-116.
27. Arndt C, Koristka S, Feldmann A, Bartsch H, Bachmann M,. Coomassie-Brilliant Blue staining of polyacrylamide gels. Methods Mol Biol 2012; 869: 465-469.
28. Koristka S, Cartellieri M, Theil A, Feldmann A, Arndt C, Stamova S, Michalk I, Töpfer K, Temme A, Kretschmer K, Bornhäuser M, Ehninger G, Schmitz M, Bachmann M,. Retargeting of human regulatory T cells by single-chain bispecific antibodies. J Immunol 2012; 188 (3): 1551-1558.
29. Morgenroth A, Cartellieri M, Schmitz M, Günes S, Weigle B, Bachmann M, Abken H, Rieber EP, Temme A,. Targeting of tumor cells expressing the prostate stem cell antigen (PSCA) using genetically engineered T-cells. Prostate 2007; 67 (10): 1121-1131.
30. Kontermann R,. Dual targeting strategies with bispecific antibodies. MAbs 2012; 4 (2): 182-197.
31. Dreier T, Baeuerle PA, Fichtner I, Grün M, Schlereth B, Lorenczewski G, Kufer P, Lutterbüse R, Riethmüller G, Gjorstrup P, Bargou RC,. T cell costimulus-independent and very efficacious inhibition of tumor growth in mice bearing subcutaneous or leukemic human B cell lymphoma xenografts by a CD19-/CD3- bispecific single-chain antibody construct. J Immunol 2003; 170 (8): 4397-4402.
32. Adler HL, McCurdy MA, Kattan MW, Timme TL, Scardino PT, Thompson TC,. Elevated levels of circulating interleukin-6 and transforming growth factor-beta1 in patients with metastatic prostatic carcinoma. J Urol 1999; 161 (1): 182-187.
33. Gruen M, Bommert K, Bargou RC,. T-cell-mediated lysis of B cells induced by a CD19xCD3 bispecific single-chain antibody is perforin dependent and death receptor independent. Cancer Immunol Immunother 2004; 53 (7): 625-632.
34. Haas C, Krinner E, Brischwein K, Hoffmann P, Lutterbüse R, Schlereth B, Kufer P, Baeuerle PA,. Mode of cytotoxic action of T cell-engaging BiTE antibody MT110. Immunobiology 2009; 214 (6): 441-453.
35. Kiessling A, Füssel S, Wehner R, Bachmann M, Wirth MP, Rieber EP, Schmitz M,. Advances in specific immunotherapy for prostate cancer. Eur Urol 2008; 53 (4): 694-708.
36. Kiessling A, Wehner R, Füssel S, Bachmann M, Wirth MP, Schmitz M,. Tumor-Associated antigens for specific immunotherapy of prostate cancer. Cancers (Basel) 2012; 4 (1): 193-217.
37. Gu Z, Thomas G, Yamashiro J, Shintaku IP, Dorey F, Raitano A, Witte ON, Said JW, Loda M, Reiter RE,. Prostate stem cell antigen (PSCA) expression increases with high Gleason score, advanced stage and bone metastasis in prostate cancer. Oncogene 2000; 19 (10): 1288-1296.
38. Ross S, Spencer SD, Holcomb I, Tan C, Hongo J, Devaux B, Rangell L, Keller GA, Schow P, Steeves RM, Lutz RJ, Frantz G, Hillan K, Peale F, Tobin P, Eberhard D, Rubin MA, Lasky LA, Koeppen H,. Prostate stem cell antigen as therapy target: Tissue expression and in vivo efficacy of an immunoconjugate. Cancer Res 2002; 62 (9): 2546-2553.
39. Ono H, Yanagihara K, Sakamoto H, Yoshida T, Saeki N,. Prostate stem cell antigen gene is expressed in islets of pancreas. Anat Cell Biol 2012; 45 (3): 149-154.
40. Thomas-Kaskel AK, Zeiser R, Jochim R, Robbel C, Schultze-Seemann W, Waller CF, Veelken H,. Vaccination of advanced prostate cancer patients with PSCA and PSA peptide-loaded dendritic cells induces DTH responses that correlate with superior overall survival. Int J Cancer 2006; 119 (10): 2428-2434.
41. Waeckerle-Men Y, Uetz-von Allmen E, Fopp M, von Moos R, Böhme C, Schmid HP, Ackermann D, Cerny T, Ludewig B, Groettrup M, Gillessen S,. Dendritic cell-based multi-epitope immunotherapy of hormone-refractory prostate carcinoma. Cancer Immunol Immunother 2006; 55 (12): 1524-1533.
42. Westdorp H, Sköld AE, Snijer BA, Franik S, Mulder SF, Major PP, Foley R, Gerritsen WR, de Vries IJ,. Immunotherapy for prostate cancer: Lessons from responses to tumor-Associated antigens. Front Immunol 2014; 5: 191.